Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 6/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | EED | O75530 | 1/20 | 0.36 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23152497 | 0.85 | HTR7 (0.46) | HTR7CYP17A1CHRM1LMNAHRH4 | |
| SCHEMBL24126771 | 0.82 | CHKA (0.52) | HTR7CYP17A1LMNAHRH4 | |
| SCHEMBL5729251 | 0.79 | LDHA (0.40) | CHRM1LMNAHRH4EED | |
| SCHEMBL5731145 | 0.79 | LMNA (0.38) | CHRM1LMNAHRH4EED | |
| SCHEMBL17893769 | 0.78 | ADRB1 (0.38) | HTR7CYP17A1CHRM1LMNA | |
| SCHEMBL3724026 | 0.77 | LMNA (0.46) | LMNA | |
| SCHEMBL1432978 | 0.77 | ADRB2 (0.56) | HTR7CHRM1HRH4 | |
| SCHEMBL1849544 | 0.77 | HRH4 (0.59) | HRH4 | |
| SCHEMBL5728966 | 0.76 | LNPEP (0.41) | CHRM1LMNAHRH4EED | |
| SCHEMBL8514674 | 0.76 | CHRM1 (0.46) | HTR7CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536710-B1 | PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-8486967-B2 | Heteroaryl substituted piperidines | HOFFMANN-LA ROCHE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| CN-103025724-A | Piperidine derivatives | HOFFMANN LA ROCHE | 2013-04-03 | — | — | CN | disclosed |
| EP-2536710-A2 | PIPERIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011101304-A2 | PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | WO | disclosed |
| US-20110201605-A1 | HETEROARYL SUBSTITUTED PIPERIDINES | HOFFMANN-LA ROCHE, INC. | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201605-A1 | HETEROARYL SUBSTITUTED PIPERIDINES | APP, HPGDS, PSEN1 | HTR7 155/4885CYP17A1 3103/4885CHRM1 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.